Company: SCLXW
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0000950170-25-047800
Chunk: 229

Company: Scilex Holding Co
Filing Date: 2025-03-31
Form: 10-K
Item: Item 1B
Chunk 229
---
2023

 126

Net Revenue

The following table summarizes net revenue by product for the years ended December 31, 2024 and 2023 (in thousands):

    Year Ended December 31,

    2024

    2023

    Increase (Decrease)

    ZTlido

    Net Revenue
     
    $
    52,094

    $
    46,300

    $
    5,794

    ELYXYB

    Net Revenue

    4,258

    443

    3,815

    GLOPERBA

    Net Revenue

    238

    —

    238

    Total Net Revenue
     
    $
    56,590

    $
    46,743

    $
    9,847

Net revenue for the years ended December 31, 2024 and 2023 was $56.6 million and $46.7 million, respectively. The increase of $9.9 million was comprised of $5.8 million, $3.8 million and $0.2 million increase in net product sales of ZTlido, ELYXYB and GLOPERBA, respectively, with GLOPERBA sales commencing in June 2024. The increase in net sales of ZTlido and ELYXYB was driven by an increase in gross sales by approximately 6% and 49%, respectively, as a result of an increase in the sales volume due to higher demand and a standard industry annual price increase, partially offset by an increase in rebates. The commercial launch of ELYXYB has been met with a strong response from the prescribing community since its commercial launch in April 2023 and continued to show growth during 2024, the first full year of commercialization. 

Cost of Revenue

The following table summarizes cost of revenue by product for the years ended December 31, 2024 and 2023 (in thousands):

    Year Ended December 31,

    2024

    2023

    Increase (Decrease)

    ZTlido

    Cost of Revenue
     
    $
    6,249

    $
    6,631

    $
    (382
    )

    Cost of Revenue - Royalties

    9,854

    8,544

    1,310

    Other Cost of Revenue

    45

    435